Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Article uri icon

Overview

authors

publication date

  • October 1, 2023

Identity

PubMed Central ID

  • PMC10597837

Scopus Document Identifier

  • 85173936644

Digital Object Identifier (DOI)

  • 10.1038/s43018-023-00663-3

PubMed ID

  • 37814012

Additional Document Info

volume

  • 4

issue

  • 10